• 2016

    1) Chan, C. K., Holroyd, C. R., Mason, A., Zarroug, J. and Edwards, C. J. (2016). “Are there dangers in biologic dose reduction strategies?” Autoimmunity Reviews 15(7): 742-746.

    2) Fong, W., Holroyd, C., Davidson, B., Armstrong, R., Harvey, N., Dennison, E., et al. (2016). “The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.” Rheumatology 55(10): 1837-1842.

    3) Holroyd, C. R., Osmond, C., Barker, D. J., Ring, S. M., Lawlor, D. A., Tobias, J. H., et al. (2016). “Placental Size Is Associated Differentially With Postnatal Bone Size and Density.” Journal of Bone & Mineral Research 31(10): 1855-1864.

    4) Sammut, L., Wallis, D. and Holroyd, C. (2016). “Progressive multifocal leukoencephalopathy associated with infliximab.” Journal of the Royal College of Physicians of Edinburgh 46(3): 163-165.


    1) Marks, J. L., Holroyd, C. R., Dimitrov, B. D., Armstrong, R. D., Calogeras, A., Cooper, C., et al. (2015). “Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?” Arthritis Care Res (Hoboken) 67(6): 746-753.


    1) Harvey, N. C., Holroyd, C., Ntani, G., Javaid, K., Cooper, P., Moon, R., et al. (2014). “Vitamin D supplementation in pregnancy: a systematic review.” Health Technology Assessment (Winchester, England) 18(45): 1-190.




    1) Holroyd, C., Harvey, N., Dennison, E. and Cooper, C. (2012). “Epigenetic influences in the developmental origins of osteoporosis.” Osteoporos.Int. 23: 401-410.

    2) Holroyd, C. R., Harvey, N. C., Crozier, S. R., Winder, N. R., Mahon, P. A., Ntani, G., et al. (2012). “Placental size at 19 weeks predicts offspring bone mass at birth: Findings from the Southampton Women’s Survey.” Placenta 33: 623-629.




    1) Cooper, C., Cole, Z. A., Holroyd, C. R., Earl, S. C., Harvey, N. C., Dennison, E. M., et al. (2011). “Secular trends in the incidence of hip and other osteoporotic fractures.” Osteoporos.Int 22: 1277-1288.

    2) Holroyd, C. R., Cooper, C. and Harvey, N. C. (2011). “Vitamin D and the postmenopausal population.” Menopause.Int. 17: 102-107.

    3) Holroyd, C. R. and Harvey, N. C. (2011). “Bone unfriendly drugs.” Osteoporosis Review 19(3): 1-6.




    1) Earl, S., Cole, Z. A., Holroyd, C., Cooper, C. and Harvey, N. C. (2010). “Session 2: Other diseases: Dietary management of osteoporosis throughout the life course.” Proc.Nutr.Soc. 69: 25-33.

    2) Holroyd, C. R., Davies, J. H., Taylor, P., Jameson, K., Rivett, C., Cooper, C., et al. (2010). “Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome.” Osteoporos.Int 21: 2093-2099.




    1) Holroyd, C., Cooper, C. and Dennison, E. (2008). “Epidemiology of osteoporosis.” Best.Pract.Res.Clin.Endocrinol Metab 22: 671-685.